Free Trial
NASDAQ:ALGS

Aligos Therapeutics Q2 2024 Earnings Report

Aligos Therapeutics logo
$7.69 -0.44 (-5.41%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$7.60 -0.09 (-1.17%)
As of 08/8/2025 05:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aligos Therapeutics EPS Results

Actual EPS
$0.75
Consensus EPS
-$4.00
Beat/Miss
Beat by +$4.75
One Year Ago EPS
-$10.75

Aligos Therapeutics Revenue Results

Actual Revenue
$1.06 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Aligos Therapeutics Announcement Details

Quarter
Q2 2024
Time
After Market Closes
Conference Call Date
Tuesday, August 6, 2024
Conference Call Time
4:00PM ET

Aligos Therapeutics Earnings Headlines

One stock to replace Nvidia
Investing Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another to rival Tesla… and a third to upset Nvidia. These little-known stocks are poised to overtake the three reigning tech darlings in a move that could completely reorder the top dogs of the stock market. Eric Fry gives away names, tickers and full analysis in this first-ever free broadcast.
See More Aligos Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aligos Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aligos Therapeutics and other key companies, straight to your email.

About Aligos Therapeutics

Aligos Therapeutics (NASDAQ:ALGS), a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

View Aligos Therapeutics Profile

More Earnings Resources from MarketBeat